JP2020513191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513191A5 JP2020513191A5 JP2019524083A JP2019524083A JP2020513191A5 JP 2020513191 A5 JP2020513191 A5 JP 2020513191A5 JP 2019524083 A JP2019524083 A JP 2019524083A JP 2019524083 A JP2019524083 A JP 2019524083A JP 2020513191 A5 JP2020513191 A5 JP 2020513191A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- vector
- group
- transcription factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 108091023040 Transcription factor Proteins 0.000 claims 9
- 102000040945 Transcription factor Human genes 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 102100023013 Basic leucine zipper transcriptional factor ATF-like 3 Human genes 0.000 claims 6
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 claims 6
- 101000903609 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 3 Proteins 0.000 claims 6
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 claims 6
- 102000043138 IRF family Human genes 0.000 claims 6
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008263 Cervical dysplasia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007877 drug screening Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 210000004966 intestinal stem cell Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000007275 lymphatic system cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108010008929 proto-oncogene protein Spi-1 Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000008672 reprogramming Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010044285 tracheal cancer Diseases 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 210000003954 umbilical cord Anatomy 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 201000011294 ureter cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT11001217 | 2017-04-05 | ||
| PT110012 | 2017-04-05 | ||
| EP17171166.6A EP3385373A1 (en) | 2017-04-05 | 2017-05-15 | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof |
| EP17171166.6 | 2017-05-15 | ||
| PT11026317 | 2017-08-24 | ||
| PT110263 | 2017-08-24 | ||
| PT110267 | 2017-08-25 | ||
| PT11026717 | 2017-08-25 | ||
| PCT/IB2018/052378 WO2018185709A1 (en) | 2017-04-05 | 2018-04-05 | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513191A JP2020513191A (ja) | 2020-05-07 |
| JP2020513191A5 true JP2020513191A5 (https=) | 2021-05-13 |
| JP7303743B2 JP7303743B2 (ja) | 2023-07-05 |
Family
ID=63712920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524083A Active JP7303743B2 (ja) | 2017-04-05 | 2018-04-05 | 細胞を樹状細胞または抗原提示細胞にリプログラムするための組成物、その方法および使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11345891B2 (https=) |
| EP (1) | EP3607055B1 (https=) |
| JP (1) | JP7303743B2 (https=) |
| CN (1) | CN110088272B (https=) |
| CA (1) | CA3040626A1 (https=) |
| DK (1) | DK3607055T3 (https=) |
| IL (1) | IL266131B1 (https=) |
| SG (1) | SG11201903353WA (https=) |
| WO (1) | WO2018185709A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201619876D0 (en) | 2016-11-24 | 2017-01-11 | Cambridge Entpr Ltd | Controllable transcription |
| JP7648543B2 (ja) * | 2019-05-27 | 2025-03-18 | ヴェストファーリッシュ ヴィルヘルム－ユニバーシテート ミュンスター | ヒト多能性幹細胞からのミクログリアの迅速かつ確定的な作製 |
| CN112574952B (zh) * | 2019-09-30 | 2025-04-15 | 英基生物医药(香港)有限公司 | 一种工程化人体免疫细胞、其制备方法及应用 |
| KR20220077916A (ko) * | 2019-10-10 | 2022-06-09 | 아스가르드 테라퓨틱스 아베 | 세포를 형질세포양 수지상 세포 또는 인터페론 유형 i-생산 세포로 재프로그래밍하기 위한 조성물, 방법 및 이의 용도 |
| WO2021087234A1 (en) * | 2019-11-01 | 2021-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Lineage reprogramming as a cancer immunotherapy |
| KR20220105161A (ko) * | 2019-11-25 | 2022-07-26 | 아스가르드 테라퓨틱스 아베 | 항원 제시를 위해 세포를 2형 수지상 세포 성분으로 재프로그래밍하기 위한 조성물, 그 방법 및 용도 |
| CA3161103A1 (en) * | 2019-12-16 | 2021-06-24 | Carl Deselm | Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same |
| US20230046425A1 (en) * | 2019-12-23 | 2023-02-16 | University Of Florida Research Foundation, Incorporated | Immunotherapy for direct reprogramming of cancer cells into immune cells/antigen presenting cells/dendritic cells |
| CA3204787A1 (en) * | 2021-02-05 | 2022-08-11 | Julie STEINBRINK | Methods to detect and treat a fungal infection |
| IL308291A (en) * | 2021-05-19 | 2024-01-01 | Asgard Therapeutics Ab | Reprogramming of cells to type 1 conventional dendritic cells or antigen-presenting cells |
| CN114252611B (zh) * | 2021-12-07 | 2022-09-27 | 暨南大学附属第一医院（广州华侨医院） | 一种筛选前列腺癌潜在生物标志物的方法及其应用 |
| CN114324126B (zh) * | 2022-01-07 | 2024-03-19 | 南京鼓楼医院 | 一种改变早期b细胞分化的方法 |
| WO2023176806A1 (ja) * | 2022-03-18 | 2023-09-21 | 国立研究開発法人産業技術総合研究所 | 線維芽細胞または線維芽細胞様細胞を従来型２型樹状細胞にリプログラミングするための方法 |
| WO2025120097A1 (en) * | 2023-12-05 | 2025-06-12 | Asgard Therapeutics Ab | Rna-based strategies for dendritic cell reprogramming and uses thereof |
| WO2026003067A1 (en) * | 2024-06-25 | 2026-01-02 | Asgard Therapeutics Ab | Transcription factors and reprogramming modulators for reprogramming cells to cdc1 cells, compositions and methods thereof |
| CN120290474B (zh) * | 2025-04-15 | 2025-12-30 | 广州正源生物技术有限公司 | 一种dc细胞的高效诱导培养试剂盒及其诱导培养方法 |
| CN121023040A (zh) * | 2025-09-30 | 2025-11-28 | 长江大学 | 与非洲猪瘟免疫相关的分子标记、引物、试剂盒及应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0746994B2 (ja) | 1984-10-04 | 1995-05-24 | 味の素株式会社 | 発酵法によるｌ−アミノ酸の製造法 |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
| JPH07501450A (ja) | 1991-11-29 | 1995-02-16 | モンサント カンパニー | 環状ジグアニレート代謝酵素 |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| EP0672161B1 (en) | 1992-11-05 | 1999-09-22 | Xyrofin Oy | Recombinant method and host for manufacture of xylitol |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| WO1996006926A1 (fr) | 1994-08-30 | 1996-03-07 | Ajinomoto Co., Inc. | Procede pour produire de la l-valine et de la l-leucine |
| JP3966583B2 (ja) | 1997-06-23 | 2007-08-29 | 協和醗酵工業株式会社 | 発酵法によるｌ−アミノ酸の製造法 |
| US8148129B2 (en) * | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
| CN105861443A (zh) * | 2007-04-07 | 2016-08-17 | 怀特黑德生物医学研究所 | 体细胞重编程 |
| US20090215875A1 (en) * | 2008-02-25 | 2009-08-27 | Deneault Eric | Methods and kits for expanding hematopoietic stem cells |
| WO2010117879A1 (en) * | 2009-04-08 | 2010-10-14 | Ld Biopharma, Inc. | Generating ips cells by protein transduction of recombinant potency-determining factors |
| CA2785832A1 (en) * | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| US8802438B2 (en) | 2010-04-16 | 2014-08-12 | Children's Medical Center Corporation | Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9228204B2 (en) * | 2011-02-14 | 2016-01-05 | University Of Utah Research Foundation | Constructs for making induced pluripotent stem cells |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2013036829A1 (en) | 2011-09-09 | 2013-03-14 | Genentech, Inc | Treatment of th17 mediated inflammatory diseases |
| WO2013116307A1 (en) * | 2012-01-30 | 2013-08-08 | Mount Sinai School Of Medicine | Method for programming differentiated cells into hematopoietic stem cells |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2014197748A2 (en) | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| WO2016120651A1 (en) * | 2015-01-30 | 2016-08-04 | Debreceni Egyetem | Runx3 dependent enhanced dendritic cell generation |
| WO2021087234A1 (en) | 2019-11-01 | 2021-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Lineage reprogramming as a cancer immunotherapy |
-
2018
- 2018-04-05 WO PCT/IB2018/052378 patent/WO2018185709A1/en not_active Ceased
- 2018-04-05 JP JP2019524083A patent/JP7303743B2/ja active Active
- 2018-04-05 DK DK18723960.3T patent/DK3607055T3/da active
- 2018-04-05 CA CA3040626A patent/CA3040626A1/en active Pending
- 2018-04-05 SG SG11201903353WA patent/SG11201903353WA/en unknown
- 2018-04-05 CN CN201880005047.3A patent/CN110088272B/zh active Active
- 2018-04-05 US US16/342,803 patent/US11345891B2/en active Active
- 2018-04-05 EP EP18723960.3A patent/EP3607055B1/en active Active
-
2019
- 2019-04-18 IL IL266131A patent/IL266131B1/en unknown
-
2022
- 2022-04-26 US US17/729,681 patent/US20220325244A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513191A5 (https=) | ||
| JP2024522074A5 (https=) | ||
| CN108251423B (zh) | CRISPR-Cas9系统特异性靶向人RSPO2基因的sgRNA及激活方法和应用 | |
| Mathison et al. | “Triplet” polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors | |
| JP5975352B2 (ja) | 癌幹細胞を標的とするウイルスベクター | |
| BR112020006746A2 (pt) | intensificador para células t ou células b, composição farmacêutica, inibidor da recorrência de tumor maligno, e, indutor para induzir uma função de memória em células t ou células b | |
| CN106754917B (zh) | 胶质母细胞瘤中同时敲除EGFRwt和EGFRvIII的方法 | |
| EP2062971A1 (en) | Chimeric adenovirus, method for producing the same and pharmaceutical using the same | |
| CA2917584C (en) | Genetically stable oncolytic rna virus, method of manufacturing and use thereof | |
| JP2021118683A (ja) | 組換えワクシニアウイルス | |
| Liebertz et al. | Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1 | |
| CN104593421A (zh) | 一种抑制胶质瘤生长的过表达bdnf的间充质干细胞的制备方法及其临床应用 | |
| Lundstrom | Viral vector-based cancer vaccines | |
| JP6235697B2 (ja) | 変異ワクシニアウイルス株、その使用およびそれを作製する方法 | |
| CN114540309A (zh) | 一种用于高效扩增rna病毒的重组细胞及其扩增方法和应用 | |
| FI3607055T3 (fi) | Koostumuksia solujen uudelleenohjelmoimiseksi dendriittisoluiksi tai antigeeniä esitteleviksi soluiksi, niiden menetelmiä ja käyttötapoja | |
| WO2021157685A1 (ja) | ヒトＴ細胞由来ｉＰＳ細胞由来の細胞傷害性Ｔ細胞 | |
| WO2016187908A1 (zh) | 重组溶瘤腺病毒及其应用 | |
| JP6915792B1 (ja) | 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス | |
| CN119120379B (zh) | 一种针对iPSC-NK细胞的嵌合抗原受体及其应用 | |
| CA3196813A1 (en) | Novel recombinant vaccinia virus and use thereof | |
| WO2021206104A1 (ja) | がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞 | |
| CN116162656B (zh) | 基因组合及其表达载体和用途 | |
| CN113583977A (zh) | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 | |
| Takigawa et al. | Antitumor effect induced by dendritic cell (DC)-based immunotherapy against peritoneal dissemination of the hamster pancreatic cancer |